Skip to main content
Figure 4 | Head & Neck Oncology

Figure 4

From: Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line

Figure 4

Western Blot showing positive E6 expression from various protein extracts. All samples were normalized with a tubulin control: a) 2A3 and FaDu cells grown in vitro; b) comparison of E6 levels in CasKi cervical cancer cells (lane1) and in 2A3 cells (lane 2). The intensity of the bands was compared using ImageJ software; c) 2A3 cells grown in vitro and treated with various concentrations of MG-132 for 3 hours. Lane 1-4 - 0, 5, 10 and 25 μg/ml MG-132, respectively; d) 2A3 and FaDu tumors in nude mice with and without treatment with 20 μg/ml of the proteasome inhibitor MG-132 3 hrs before extraction of the tumors (lanes 1 and 2 - 2A3, lanes 3 and 4 - FaDu).

Back to article page

Head & Neck Oncology

ISSN: 1758-3284